ÐÂÎŶ¯Ì¬

ÒýÑÔ

ÔÚʵÌåÁöµÄ¾Ö²¿·ÅÉäÖÎÁÆÁìÓò£¬µâ125£¨I-125£©·ÅÉäÐÔ·â±ÕÁ£×Óƾ½èÆäÎȶ¨µÄ·øÉäÐÔÄܳ¤ÆÚÕ¼¾ÝÖ÷µ¼µØλ¡£È»¶ø£¬Ëæמ«×¼Ò½ÁƵķ¢Õ¹£¬´«Í³µâ125Á£×ÓÖ²ÈëµÄ¾ÖÏÞÐÔÈÕÒæ͹ÏÔ£º²»¿É½µ½â²ÄÁϵ¼ÖÂÒìÎï²ÐÁô¡¢µ¥´ÎÖ²Èë¼ÁÁ¿¹Ì¶¨¡¢·øÉäÄÜÁ¿µ¥Ò»¼°Á£×ÓǨÒƵÈÎÊÌ⣬ÑÏÖØÖÆÔ¼ÁËÆäÔÚ¸´ÔÓÁÙ´²³¡¾°ÖеÄÓ¦ÓÃÍØÕ¹¡£Ôڴ˱³¾°Ï£¬ÒÔÎÂÃôÀ൯ÐÔµ°°×ΪÔØÌåµÄÐÂÐÍÄÚ·ÅÉäºËËØÒ©ÎELP-BT£©Ñз¢³É¹¦¡£Æ¾½èÆä¿É×¢Éä¡¢¿É½µ½â¡¢¿ÉЯ´ø¶àÖÖͬλËØ¡¢Ïà±äð¤Á¬¹Ì¶¨·ÅÉäÔ´µÈÓÅÊÆ£¬ÓÐÍû³ÉΪ´«Í³·ÅÉäÐÔÁ£×ӵŦÄÜÐÔÌæ´úºÍ»¥²¹ÁÆ·¨£¬ÎªÊµÌåÁöµÄ¾Ö²¿ÄÚ·ÅÉäÖÎÁÆ¿ª±Ù¸ü¹ãÀ«µÄÁÙ´²Ó¦ÓÃÇ°¾°¡£

1¡¢µâ-125Á£×ӵľÖÏÞÐÔ

½üÄêÀ´£¬ÔÚÎ÷·½¹ú¼ÒÁÙ´²Éϵâ-125·ÅÉäÐÔ·â±ÕÁ£×Ó±»¹ã·ºÓ¦ÓÃÓÚÓÀ¾ÃµÍ¼ÁÁ¿£¨Low-dose-rate, LDR£©½ü¾àÀë·ÅÉäÐÔÖÎÁÆ¡£ÓÈÆäÔÚÔçÆÚÇ°ÁÐÏÙ°©£¨Prostate cancer, PCa£©ÖÎÁÆÖУ¬¸Ã¼¼ÊõÕ¹ÏÖ³öÏÔÖøÁÆЧ£ºÖ²Èëºó 15 ÄêµÄ³¤ÆÚËæ·ÃÊý¾Ý±íÃ÷£¬»¼Õß×ÜÌåÉú´æÂÊ´ï 81%£¬PCaÌØÒìÐÔÉú´æÂʸߴï 95%^[1]¡£´ËÍ⣬µâ-125 Á£×Ó½ü¾àÀë·ÅÁƵÄÓ¦Ó÷¶Î§ÒÑÍØÕ¹ÖÁÍ·¾±²¿Ö×Áö¡¢·Î°©¡¢ÈéÏÙ°©¡¢Ö±³¦°©µÈ¶àÖÖʵÌåÁö£¬¾ùÈ¡µÃÁËÁ¼ºÃµÄÖÎÁÆЧ¹û^{[2, 3]}¡£¾¡¹Ü¹²⁵£É·ÅÉäÐÔ·â±ÕÁ£×ÓÔÚÁÙ´²¹ã·ºÓ¦Óã¬ÓÈÆäÔÚÔçÆÚPCaÖÎÁÆÖлñµÃ¸ß¶ÈÁÙ´²ÈÏ¿É£¬±»ÈÏΪÊÇÒ»ÖÖ°²È«ÓÐЧµÄ¡¢²¢·¢Ö¢µÍµÄÖÎÁÆÊֶΣ¬µ«»¹ÊÇ´æÔÚһЩ¾ÖÏÞÐÔ£¬°üÀ¨£º

£¨1£©ÒÀÀµ¾«Õ¿µÄÍâ¿Æ²Ù×÷¼¼Êõ£¬Í¨¹ýÖ²ÈëÊÖÊõ½«Ò»¶¨Á¿£¨80-120¸ö£©Á£×ÓÖ²ÈëÕû¸ö£¨Ç°ÁÐÏÙ£©Ö×Áö¡£¾«×¼²¼Ô´²»½öÐèÑϸñ×ñÑ­ÖÎÁƼƻ®£¬¸üÒÀÀµÊõÕß³¤ÆÚÅàѵ»ýÀ۵IJÙ×÷¾­Ñ飻

£¨2£©¶ÔÖÜΧ×éÖ¯µÄ·øÉäËðÉË¿ÉÒý·¢ÏÔÖø¸±×÷ÓãºÔÚÇ°ÁÐÏÙ°©ÖÎÁÆÖУ¬Á£×Ó·ÅÖò»µ±¿ÉÄܵ¼ÖÂÃÚÄòÉúֳϵͳ²¢·¢Ö¢£¨ÈçÄòʧ½û¡¢ÐÔ¹¦ÄÜÕÏ°­£©¼°Á£×ÓÒÆλ£»´ËÍ⣬¹Ì¶¨ËùÓÐÁ£×ÓµÄλÖÃÐè½øÐÐ10-20´ÎµÄÕë²å£¬ÕâÖÖÓд´²Ù×÷Ò×ÓÕ·¢Ç°ÁÐÏÙË®Ö×ÐÔÑ×Ö¢·´Ó¦£¬µ¼Ö»¼ÕßÐèÁôÖõ¼Äò10ÌìÒÔÉÏ£»

£¨3£©µ¥Ò»ºËËØ£¨ÈçI-125£©µÄÄÜÁ¿ÌØÐÔÏÞÖÆÁËÆäÔÚ·¦Ñõ»ò´óÌå»ýÖ×ÁöÖÎÁÆÖеÄÓ¦Ó㬲¢ÇÒ¸´ÔÓµÄÊÖÊõÁ÷³Ì¼°ÇÖÈëÐÔ²Ù×÷Ôö¼ÓÁË»¼Õß´´É˸ºµ£ºÍÖÎÁƳɱ¾£»

£¨4£©ÔÚÖÎÁƹý³ÌÖÐÁ£×ÓµÄǨÒÆ£¬½«µ¼ÖÂÖÎÁƼƻ®Ê§°ÜºÍ¶¾ÐÔ²úÉú¡£

½üÄêÀ´£¬ÖÇÄܸ߷Ö×Ó²ÄÁÏÔØÌåµÄÑз¢È¡µÃÍ»ÆÆÐÔ½øÕ¹£ºÀûÓÃÆä¿É×¢É䣬¿É×Ô×é×°»òÄý¼¯½»Áª³ÉÒ»¸öÕûÌåµÄ“Á£×Ó”£¬ÓÐЧ±ÜÃâÁË´«Í³Á£×ÓµÄÒÆλ·çÏÕÓë·Ö²¼²»¾ùȱÏÝ£»Í¬Ê±£¬ÔÚÓ°ÏñÖ¸µ¼Ï£¬ÆäÔÚÖ×ÁöÄڵķֲ¼¿É¿Ø£¬¸üÓÐÀûÓÚ·ÅÉäͬλËØÔÚÖ×ÁöµÄ¾ùÔÈ·Ö²¼£¬ÎªÉÏÊöÁÙ´²ÄÑÌâÌṩÁË´´ÐÂÐÔ½â¾ö·½°¸^{[4, 5]}¡£

2¡¢ELP-BT½éÉÜ

À൯ÐÔµ°°×¶àëÄ£¨Elastin-like polypeptide£¬ELP£©ÊÇÒ»ÖÖÑÜÉúÓÚÌìÈ»ÈËÌåÖеĵ¯ÐÔµ°°×£¬Í¨¹ý»ùÒòÖØ×é¼¼ÊõÈ˹¤ºÏ³ÉµÄÎÂÃôÐÔÉúÎï¿É½µ½â¶àëľۺÏÎï¡£ÆäºËÐÄÓÅÊÆÔÚÓھ߱¸¾«×¼¿Éµ÷µÄζÈÏìÓ¦ºÍ¿ÉÄæÏàת±äÌØÐÔ——µ±»·¾³Î¶ȵÍÓÚÏà±äζȣ¨Tt£©Ê±³ÊҺ̬£¬³¬¹ý Tt ÔòѸËÙÄý¼¯¡£ELPµÄÏà±äζȿɾ«×¼É趨ΪµÍÓÚÌåΣ¨~20¡æ£©£¬ÔÚÊÒΣ¨23¡æ£©»·¾³Ï³ÊҺ̬±ãÓÚ×¢É䣬¶øµ±×¢ÈëÖ×Áö×éÖ¯ºó£¬Î¶ÈÉý¸ß£¨≥33¡æ£©£¬Ê¹ELP·¢ÉúÏà±äÄý¼¯¡£ÕâÖÖÎÂÃôÐÔÏìÓ¦»úÖÆʹµÃÓëELPżÁªµÄ·ÅÉäºËËØ£¬Äܹ»Í¨¹ýζȴ¥·¢µÄÎïÀí궨ЧӦ£¬±»¸ßЧÖÍÁôÓÚ×¢É䲿λ£¬ÊµÏÖ·ÅÉäºËËØÔÚÖ×ÁöÄڵľֲ¿³ÖÐøË¥±äÊÍ·Å·øÉäÄÜ£¬·¢»Ó´ÓÀïÖÁÍâµÄÖ×ÁöɱÉË×÷Óã¬Ó¦ÓúÏÊʵÄÖÎÁƼƻ®ºó£¬¾«×¼É趨°²È«Çø±ß½ç£¬»¹¿É¼õÉÙ¶ÔÖÜΧÕý³£×éÖ¯µÄ·øÉäËðÉË¡£´ËÍ⣬ELP³ýÁ˿ɺÉÔØ·ÅÉäµâÍ⣬»¹ÄܸßЧ¸ºÔØÆäËûα»òβ·ÅÉäÐÔºËËØ£¨ÈçAt-211, R-225¡¢Y-90¡¢Lu-177µÈ£©£¨Í¼1£©¡£

»ùÓÚÒÔÉÏÌØÐÔ£¬jxf¼ªÏé·»¹Ù·½app¿ª·¢ÁËÒ»¿îÐÂÐÍELP-BT£¬²¢Íê³ÉÁËÁÙ´²Ç°Ñо¿¡£¾­¹ý½¨¿â£¬É¸Ñ¡ºÍÐÔÄÜÆÀ¼Û£¬ÓÅ»¯ºóµÄELPµÄTt< 25°C£¬ÔÚÁöÄÚ×¢Éäºó¿ÉѸËÙ·¢ÉúÏà±äÄý¼¯£¬ÊµÏÖºËËØÔÚÖ×ÁöÄÚµÄÎȶ¨ÖÍÁô£¨ÖÍÁôʱ¼ä>60Ì죩¡£ÔÚÍ·¾±²¿ÁÛ°©Ä£ÐÍÖУ¬ÒÔ2 mCi/150 mm³¼ÁÁ¿½øÐоֲ¿×¢Éäºó£¬Ö×ÁöÍêÈ«»º½âÂÊ´ï100%£¬ÇÒÈ«Éí¶¾ÐÔ¿É¿Ø£¬ÌåÄÚ·Ö²¼·ûºÏÔ¤ÆÚ£¨Í¼1£©¡£Ä¿Ç°£¬¸ÃÒ©ÎïÒÑÍê³ÉϵͳµÄ³ÉÒ©ÐÔÆÀ¼Û£¬¾ß±¸×¨Àûת»¯Ìõ¼þ£¬ÔÚÖÎÁƼƻ®ÏµÍ³¿ª·¢ºó£¬¿ÉʵʩÁÙ´²×ª»¯¡£±¾Ñо¿ÎªÊµÌåÁöÌṩÁË¿É×¢Éä¡¢¿É½µ½â¡¢Áé»î»¯¡¢¶àģ̬ЭͬµÄ·ÅÉäÖÎÁÆвßÂÔ£¬ÓÐÍûÍ»ÆÆ´«Í³¾Ö²¿ÄÚ·ÅÉäÖÎÁƼ¼ÊõµÄ¾ÖÏÞÐÔ¡£ÆäÓÅÒìµÄÁÙ´²Ç°Ñо¿½á¹û±íÃ÷£¬¸Ã¼¼Êõ¾ß±¸Ã÷È·µÄÁÙ´²×ª»¯Â·¾¶¡£

µ±Ç°ÉÐÐ迪·¢ÊÊÅäÓÚELP-BTµÄ¾«×¼ÖÎÁƼƻ®ÏµÍ³£¨Èç·ÅÉäÁ£×ÓµÄÖÎÁƼƻ®£©£¬½è´Ë¾«×¼¼Æ»®ELP-BTµÄ×¢ÉäÁ¿ºÍλÖã¬Ô¤²âÖ×ÁöµÄÖÎÁÆÌå»ýºÍ°²È«±ß½ç£¬´Ó¶ø´ïµ½Ïû³ýÖ×ÁöÈ´²»Ó°Ï콡¿µÖÜΧ×éÖ¯µÄÄ¿µÄ¡£Î´À´×ª»¯³É¹¦ºó£¬ELP-BTÓÐÍû³ÉΪ½ðÊô·ÅÉäÁ£×ÓµÄÖØÒª²¹³äºÍÌæ´úÒ©Æ·£¬ÎªÍíÆÚʵÌåÁöµÄÖÎÁÆÔöÌíÒ»ÖÖ°²È«¡¢¸ßЧµÄÐÂÐÍÁÆ·¨¡£

 

ͼ1. ELPÌØÐÔºÍELP-BTµÄ¿¹Ö×Áö×÷ÓÃ

 

3¡¢±È½Ï·ÅÉäÐÔ·â±ÕÁ£×ӺͿÉ×¢ÉäELP-BT

3.1 ²ÄÁϸïÃü£º´Ó"ÒìÎï²ÐÁô"µ½"ÌåÄÚ½µ½â"

´«Í³µâ125Á£×Ó£º²ÉÓÃîѺϽðÍâ¿Ç·â×°£¬ÊõºóÓÀ¾Ã´æÁôÌåÄÚ£¬Ôì³ÉÉíÌåºÍÐÄÀíÉϵIJ»ÊÊ£¬»¹¿ÉÄÜÒý·¢ÂýÐÔÑ×Ö¢»ò×éÖ¯ÏËά»¯¡£ELP-BTÍ»ÆƵ㣺ÔÚÍê³É·ÅÉäÖÎÁÆʹÃüºó£¬ÔØÌå²ÄÁÏÖð²½½µ½â³É°±»ùËᣬΪÈËÌåÓªÑøËùÓ㬱ÜÃâÒìÎï·´Ó¦£¬ÏÔÖø½µµÍ³¤ÆÚ²¢·¢Ö¢·çÏÕ¡£

3.2 ÖÎÁÆ·½Ê½¸ïУº´Ó¸´ÔÓµÄ"ÊÖÊõÖ²Èë"µ½¼òµ¥µÄ"΢´´×¢Éä"

µâ125Á£×Ó£º¾¡¹Ü¹²⁵IÁ£×ÓÖÎÁƶÔÖ×Áö¾ßÓÐÃ÷È·µÄɱÉË×÷Óã¬ÇÒ¶ÔÖÜΧÕý³£×éÖ¯ËðÉËС£¬µ«ÈÔ´æÔÚÏÔÖøµÄ¾ÖÏÞÐÔ£ºÐèͨ¹ýÖ²ÈëÕë·´¸´´©´ÌʵÏÖÁ£×ÓÖ²È룬´©´Ì¹ý³ÌÖпÉÄÜÒòÉî¶È¿ØÖÆÆ«²î»ò¶à´Î´ÌÈ룬½«²»¿É±ÜÃâµØµ¼Ö¾ֲ¿·ÅÉäÐÔÑ×Ö¢·´Ó¦¡¢Ë®Öס¢»µËÀ¡¢ÐγÉÀ£ÑñºÍÏû»¯µÀ³öѪµÈÑÏÖز¢·¢Ö¢£»Í¬Ê±£¬Á£×ÓÖ÷ŵÄ׼ȷÐԸ߶ÈÒÀÀµÊõÕߵľ­ÑéºÍ¾«Õ¿¼¼Êõ£¬ËùÒÔÐèÒª¾­Ñé»ýÀÛºÍÅàѵ²ÅÄÜÕÆÎÕÖ²Èë¼¼Êõ¡£ÈôÄÜͨ¹ýÉúÎïÔØÌåЯ´ø·ÅÉäºËËØ£¬Í¨¹ýÁöÄÚ¼òµ¥×¢ÉäÍê³É·ÅÉäºËËØÖ²È룬ƾ½è²Ù×÷Á÷³Ì¼ò±ã¿É¿Ø¡¢¿É¾«×¼¿ØÖÆÒ©Îï·Ö²¼Éî¶ÈµÄÌØÐÔ£¬¹æ±Ü´«Í³ÊÖÊõµÄ¸´ÔÓÐÔ¼°Á£×ÓÕë·´¸´´©´Ì·çÏÕ£¬ÎÞÒÉΪʵÌåÁöµÄÖÎÁÆÌṩÁËÒ»ÖÖ¸üΪ°²È«¡¢±ã½ÝµÄÖÎÁÆ·½Ïò¡£ELP-BTÍ»ÆƵ㣺ͨ¹ýԤװʽעÉäÆ÷½«ELP-BTÖ±½Ó×¢ÉäÖÁÖ×Áö°ÐÇø£¬ÀûÓÃÖ×ÁöµÄζȣ¨>33°C£©ÓëELPÏà±äζȣ¨20°C£©µÄÌìÈ»ÌݶȲ´¥·¢ELPµÄÎÂÃôÏà±ä£¬ÁöÄÚ×¢ÉäºóÁ¢¼´ÔÚÖ×Áö×éÖ¯¼ä϶Äý¼¯¹Ì¶¨£¬ÐγɸßÃܶȷøÉ䳡¡£ÕâÒ»¼¼Êõ²»½ö¼ò»¯²Ù×÷Á÷³Ì¡¢½µµÍÒ½»¼·øÉ䱩¶·çÏÕ£¬¸üÊÊÓÃÓÚÉÖ×Áö»ò¸´ÔÓ½âÆʲ¿Î»Ö×ÁöµÄ¾«×¼ÖÎÁÆ¡£

3.3 ¶¯Ì¬µ÷¿Ø£º´Ó"µ¥´Î¼ÁÁ¿¹Ì»¯"µ½"Áé»î¶à´Î¸øÒ©"

µâ125Á£×Ó£º°ëË¥ÆÚ³¤£¨60.1Ì죩£¬µ¥´ÎÖ²Èëºó¼ÁÁ¿ÎÞ·¨µ÷Õû£¬¿ÉÄÜÔì³ÉÔçÆÚ¼ÁÁ¿²»×ã»òÍíÆÚ·øÉä¹ýÁ¿¡£ELP-BTÍ»ÆƵ㣺ELPµÄºËËرê¼Ç¿ÉÔÚÊõǰʵʱÍê³É£¬Ö§³Ö¸ù¾ÝÖ×ÁöÍËËõÇé¿ö¶¯Ì¬·Ö´Î×¢É䣬´Ó¶øʵÏÖ·ÅÉä¼ÁÁ¿·Ö²¼µÄ¶¯Ì¬ÓÅ»¯£»²¢ÇҾ߱¸¶àÖÖºËËرê¼ÇÄÜÁ¦£¬¶ÔÖÎÁÆÏà¶Ô²»Ãô¸ÐµÄÖ×Áö£¬¿É¼°Ê±¸ü»»ºËËØÀàÐÍ£¨±ÈÈçÓøßɱÉËÄÜÁ¦µÄαºËËØÌæ»»µÍɱÉ˵ÄβºËËØ£©£»Í¬Ê±£¬½áºÏÓ°ÏñÒýµ¼¼¼Êõ£¬¿ÉʵÏÖ"¼ÁÁ¿»æ»­"£¨Dose Painting£©£¬ÓÈÆäÊÊÓÃÓڱ߽粻Çå»ò½þÈóÐÔÉú³¤µÄÖ×Áö¾«×¼ÖÎÁÆ¡£

3.4 ÄÜÁ¿Ð­Í¬£º´Ó"µ¥Ò»Í¬Î»ËØ"µ½"¶àºËËØÁªÓÃ"

µâ125Á£×Ó£º½öÊͷŵÍÄÜγÉäÏߣ¨35.5 keV£©£¬´©Í¸Á¦Èõ£¬¶ÔÌå»ý½Ï´ó»òÒìÖÊÐÔÖ×Áö¸²¸ÇÂÊÓÐÏÞ¡£ELP-BTÍ»ÆƵ㣺ÔØÌå¿É¸ºÔØβºËËØ£¬Èçµâ-131£¨I-131£©£¬îÆ-90£¨Y-90£©¡¢ïå-177£¨Lu-177£©»òαºËËØ£¬ï¹-225£¨Ac-225£©¡¢ïç-211£¨La-211)µÈ¶àÖÖͬλËØ£¬Í¨¹ý»ìºÏÔØÒ©»òÐò¹á×¢É䣬ʵÏÖ²»Í¬ÉäÏßÄÜÁ¿£¨β/ᣩÓë°ëË¥ÆÚµÄ×éºÏ¡£ÀýÈ磺Y-90£¨βÉäÏߣ©£ºÉ´©Í¸£¬Õë¶ÔÌå»ý½Ï´óÖ×Áö£»Lu-177£¨β/γÉäÏߣ©£º¼æ¾ß¾Ö²¿É±ÉËÓëÈ«ÉíÏÔÏñ¹¦ÄÜ£»¶¨ÖÆ»¯·½°¸£º¸ù¾ÝÖ×ÁöÀàÐÍ¡¢´óС¼°ÖÜΧÃô¸ÐÆ÷¹Ù£¬Éè¼Æ¸öÐÔ»¯ºËËØ"¼¦Î²¾Æ"¡£

3.5 Õ³Á¬ÖÜΧ×éÖ¯±ÜÃâ“Á£×ÓǨÒÆ”

µâ125Á£×Ó£ºµâ125Á£×ÓÇ°ÁÐÏÙ½ü¾àÀëÖÎÁƵÄÁÙ´²Ñо¿ÏÔʾ£¬ÊõºóÁ£×ÓǨÒÆÂÊΪ28.8%£¨320ÀýÖÐ92Àý£©^[6]¡£ELP-BTÍ»ÆƵ㣺¼ÈÍùÑо¿·¢ÏÖ£¬ELPÁöÄÚ×¢Éäºó·¢ÉúÏà±äÄý¼¯£¬Æ䵯ÐÔµ°°×»ùÖÊÓëÖÜΧ×éÖ¯ÐγÉÉúÎï𤸽£¬Ê¹×¢ÉäÇøÓòÐÎ̬ÔÚÊýÌìÄÚ±£³ÖÎȶ¨¡£ÕâÖÖÎïÀí𤸽ÌØÐԿɽ«·ÅÉäÁ£×Ó궨ÓÚ×¢ÉäÇøÓò£¬±ÜÃâÁ˽ðÊôÁ£×ÓµÄǨÒÆ¡£

4¡¢×ܽá

×ÛÉÏËùÊö£¬ELPƾ½èÎÂÃôÏà±äÄý¼¯¡¢¿É½µ½â¡¢¿É×¢Éä¡¢¿ÉÖظ´¸øÒ©ºÍ¿ÉÊÊÅä¶àÖÖ·ÅÉäÐÔºËËصÄÌØÐÔ£¬½áºÏרÊôÖÎÁƼƻ®ÏµÍ³ºÍ¸øÒ©×¢Éä×°Öã¬ÖØËֲܾ¿ÄÚ·ÅÉäÖ×ÁöÖÎÁÆģʽ£¬ÊµÏÖÍíÆÚʵÌåÁöµÄ¾«×¼¿ØÖÆ¡£ÎÂÃôELP-BTͨ¹ý¾«×¼¿ØÊÍ¡¢Áé»îÖÎÁƵÈÓÅÊÆ£¬¿ÉÓÐЧ²¹³ä»òÌæ´ú²»¿É½µ½âµÄÃÜ·â×ÑÔ´µÄÁÙ´²¾ÖÏÞÐÔ£¬Ô¤Ê¾ÆäÔÚÍíÆÚʵÌåÁöÖÎÁÆÁìÓò½«¾ß±¸ÏÔÖøµÄ¾ºÕùÁ¦¡£Î´À´Ñо¿Ðè½øÒ»²½ÓÅ»¯ELPµÄ·Ö×ÓÉè¼Æ¡¢ÌáÉýºËËظºÔØЧÂʲ¢Ì½Ë÷ÁÙ´²ÁªºÏÖÎÁÆ·½°¸£¬ÒÔ¼ÓËÙÆä´ÓʵÑéÊÒÏòÁÙ´²´²ÅÔµÄת»¯Ó¦Óã¨Í¼2£©¡£

ͼ2. I-125ÃÜ·â×ÑÔ´´æÔÚÎÊÌâºÍELP-BTµÄ½â¾ö·½·¨

 

²Î¿¼ÎÄÏ×

• 1.Uribe-Lewis, S., et al., Long-term survival after low-dose-rate brachytherapy for prostate cancer: the  Royal Surrey experience. BJU Int, 2022. 129(6): p. 723-730.
• 2.Wei, S., et al., Radioactive Iodine-125 in Tumor Therapy: Advances and Future Directions. Front Oncol, 2021. 11: p. 717180.
• 3.ÕÔÃ÷ÐǵÈ, ½ü¾àÀë·ÅÉäÖÎÁÆÔÚÏû»¯ÏµÖ×ÁöÖÎÁÆÖеÄÓ¦ÓÃÇ°¾°. ¹ú¼ÊÏû»¯²¡ÔÓÖ¾, 2013. 33(03): µÚ160-164+179Ò³.
• 4.Seniwal, B., et al., Recent Advances in Brachytherapy Using Radioactive Nanoparticles: An Alternative  to Seed-Based Brachytherapy. Front Oncol, 2021. 11: p. 766407.
• 5.Liu, W., et al., Brachytherapy using injectable seeds that are self-assembled from genetically  encoded polypeptides in situ. Cancer Res, 2012. 72(22): p. 5956-65.
• 6.Miyazawa, K., et al., Seed migration after transperineal interstitial prostate brachytherapy with I-125  free seeds: analysis of its incidence and risk factors. Jpn J Radiol, 2012. 30(8): p. 635-41.

*ÉùÃ÷£º±¾ÎĽöÊǽéÉÜÒ½Ò©¼²²¡ÁìÓòÑо¿½øÕ¹»ò¼òÊöÑо¿¸Å¿ö»ò·ÖÏíÒ½Ò©Ïà¹ØѶϢ£¬²¢·ÇÒ²²»»á½øÐÐÖÎÁÆ»òÕï¶Ï·½°¸ÍƼö£¬Ò²²»¶ÔÏà¹ØͶ×ʹ¹³ÉÈκν¨Òé¡£